Comparative Pharmacology
Head-to-head clinical analysis: IMDUR versus NITRONAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IMDUR versus NITRONAL.
IMDUR vs NITRONAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Isosorbide mononitrate is a nitrate vasodilator that relaxes vascular smooth muscle via conversion to nitric oxide (NO), which activates guanylate cyclase, increasing cGMP levels, leading to vasodilation. It primarily dilates veins (venodilation) with lesser effects on arteries, reducing preload and afterload, thereby decreasing myocardial oxygen demand.
Nitronal (nitroglycerin) is a vasodilator that works by releasing nitric oxide, which activates guanylate cyclase and increases cyclic guanosine monophosphate (cGMP) in vascular smooth muscle, leading to relaxation and dilation of peripheral arteries and veins, predominantly venous dilation.
Initial: 30-60 mg orally once daily; titrate to 120 mg once daily as tolerated. Maximum: 240 mg once daily.
Initial intravenous infusion of 5 mcg/min, titrated by 5 mcg/min every 3-5 minutes to clinical effect; typical maintenance 10-200 mcg/min.
None Documented
None Documented
Terminal elimination half-life of isosorbide mononitrate is approximately 5 hours. This supports once-daily dosing for IMDUR (extended-release formulation) due to prolonged absorption phase.
Terminal elimination half-life is 1-4 minutes (due to rapid hepatic metabolism via glutathione S-transferase). Clinical context: necessitates continuous IV infusion for sustained effect.
Isosorbide dinitrate (IMDUR active metabolite? Actually IMDUR is isosorbide mononitrate, the active metabolite of isosorbide dinitrate. For isosorbide mononitrate: renal excretion is approximately 96% as metabolites, with about 2% unchanged; biliary/fecal excretion is minimal, <2%.
Renal: ~60% as inactive metabolites; fecal: ~35% via bile; unchanged drug: <1%.
Category C
Category C
Nitrate Vasodilator
Nitrate Vasodilator